SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report: May 24, 2001
INNOVATIVE MEDICAL SERVICES
-------------------------------------------------------
(Exact name of registrant as specified in its charter)
California 33-0530289
------------------------------------------------------------
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification No.)
1725 Gillespie Way, El Cajon, California 92020
----------------------------------------------------------------
(Address of principal executive offices)(Zip Code)
(619) 596 8600
-----------------
(Registrant's telephone number, including area code)
EXPLANATORY NOTE ON AMENDMENT
The Registrant has filed this Amendment in response to comments received from
the staff of the U.S. Securities and Exchange Commission. The Amendment has
revised the following sections:
Exhibits
Item 5. Other Information
Officers of the Registrant, including its President Michael Krall, and Andrew
Arata, the inventor of Axenhol and president of IMS's wholly owned subsidiary,
ETI-H2O Corp., made their own, separate presentation of information to
shareholders of NVID International Inc., attending the NVID annual meeting in
Clearwater, Florida on May 21, 2001.
The presentation was to address apparent discrepancies between recent statements
made by NVID in its annual report and other Securities and Exchange Commission
filings relative to Manufacturing, Licensing And Distribution Agreement by and
between NVID International, Inc., Innovative Medical Services, ETI H20, Inc.,
dated March 26, 2000 as well as the previously disclosed current status of
testing, selling and various regulatory applications relative to Axenohl.
The Registrant has filed the Manufacturing, Licensing And Distribution Agreement
by and between NVID International, Inc., Innovative Medical Services, ETI H20,
Inc., dated March 26, 2000 as an exhibit to this Form 8-K.
Item 7. Financial Statements and Exhibits.
(C) Exhibits
10.2 Manufacturing, Licensing And Distribution Agreement by and
between NVID International, Inc., Innovative Medical Services,
ETI H20, Inc., dated March 26, 2000
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunder duly authorized.
INNOVATIVE MEDICAL SERVICES
---------------------------
(Registrant)
By /s/ Michael L. Krall
--------------------
Michael L. Krall, President
October 17, 2001